Monogenic and Syndromic Obesity: Therapeutic Implications
Canadian Diabetes & Endocrinology Today · 2024
DOI: 10.58931/cdet.2024.2334 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Diabetes & Endocrinology Today, 2024. Verfasst von Stasia Hadjiyannakis. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Obesity is a complex, progressive and relapsing neuroendocrine condition, characterized by disordered communication between the gastrointestinal tract, adipocytes and the hypothalamus. It is a heterogeneous condition with unique etiologies, broadly classified as: polygenic obesity, monogenic obesity, syndromic obesity and secondary obesity.2 The most common form of obesity is polygenic, a highly hereditable condition that involves the clustering of genes that increase the risk for obesity. This inherited genetic risk is exploited by socio-biologic exposures. Monogenic and syndromic obesity result from rare genetic mutations and are characterized by early onset severe obesity and hyperphagia. Secondary obesity may occur as a result of medication exposures, hypothalamic damage or primary endocrine disorders. Accurate classification of obesity is critical to inform surveillance and management strategies, decrease health risk and improve quality of life through newly available targeted therapies.
Zitieren
APA
Hadjiyannakis, S. (2024). Monogenic and Syndromic Obesity: Therapeutic Implications. Canadian Diabetes & Endocrinology Today. https://doi.org/10.58931/cdet.2024.2334
Vancouver
Hadjiyannakis S. Monogenic and Syndromic Obesity: Therapeutic Implications. Canadian Diabetes & Endocrinology Today. 2024. doi:10.58931/cdet.2024.2334
BibTeX
@article{Hadjiyannakis2024,
author = {Hadjiyannakis, Stasia},
title = {Monogenic and Syndromic Obesity: Therapeutic Implications},
journal = {Canadian Diabetes & Endocrinology Today},
year = {2024},
doi = {10.58931/cdet.2024.2334}
}
EUVIMED